Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VSL#3 in NAFLD
NCT03511365Phase 2Terminated
- Sponsor
- Northwell Health
- Start
- May 2018
- Primary completion
- Dec 2018
- Modality
- Multi-strain Products
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VSL#3 in non-alcoholic fatty liver disease (NAFLD), sponsored by Northwell Health. Primary endpoint: Change in Interleukin-17 levels at 8 weeks. Started May 2018; status: terminated.
02
Drugs
VSL#3
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03511365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511365.